Jenny Wu

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

Brian T. Fife, Kristen E. Pauken, Todd N. Eagar et al. · Nature Immunology · 2009 · 743 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Arnon P. Kater, John F. Seymour, Peter Hillmen et al. · Journal of Clinical Oncology · 2018 · 301 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2020 · 220 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical Procedures

Anne Knisely, Zhen Ni Zhou, Jenny Wu et al. · Annals of Surgery · 2020 · 161 citations · Full text

Medicine, Perioperative Medicine, Surgery +12

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2022 · 151 citations · Full text

Medicine, Oncology, Pharmacotherapy +15